Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$11.5B
134M shares
52-week range
$54.15 – $101.40
67% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
CS
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
www.globusmedical.comNo one on the platform currently holds GMED.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 330,463 | $28.5M |
| Renaissance Technologiesas of 2025-09-30 | 243,918 | $14.0M |
No one on the platform has traded GMED yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$GMED , Cash generating machine, zero debt, world class business agility to handle a CEO transition or on-board a competitor with virtually no business disruption, product engineering excellence, expanding product portfolio, expanding margins, tight control of expenses, outstanding business strategy and vision... why would you not 'invest' in this company ? I know this is site for traders and speculators but some part of your portfolio should be long on a proven high quality company in this market sector... easy money over the long term.
View on StockTwits ↗$GMED Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $1.12 down -25.33% YoY • Reported revenue of $789.61M up 5.94% YoY • Globus Medical reaffirms its full-year 2026 revenue guidance in the range of $3.18 billion to $3.22 billion and updates its non-GAAP fully diluted EPS guidance to $4.95 to $5.05 per share.
View on StockTwits ↗$GMED reports after the close, Estimize Consensus +0.17 EPS and +34.16M Revs compared to WS http://www.estimize.com/gmed/fq2-2026?utm_conte
View on StockTwits ↗$GMED PM pump, accumulation good and perking up. Run to close?
View on StockTwits ↗$GMED Basically a 25% return on the table. BUY. Nearly every analyst has a buy and $100 plus price target. Nice.
View on StockTwits ↗$GMED Truist Securities cuts target price to $100 from $115
View on StockTwits ↗$GMED Yeah, Baby, Yeah!!! Big GMED cowbell accumulation.
View on StockTwits ↗$GMED Looks good, two nice days. Easy buy and hold. FIRM RATING PRICE TARGET BMO Outperform $94–$100 RBC Outperform $115 WF Overweight $103 BOA Buy $106 Piper Overweight $115 Needham Buy $117 Stifel Hold $95 Nice stock to be in if you love Moderna. $MRNA is pure explosive growth story. Globus Medical has profits AND growth. Yes, still have Moderna - we've seen these pull backs many times. Moderna is up like 200% and so much more coming. Do not sell Moderna to buy this, sell your losers.
View on StockTwits ↗$GMED Easy buy, open way overdone. RBC Capital maintained an Outperform rating on Globus Medical GMED. The firm has adjusted its price target for the stock down from $120.00 to $115.00.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.